AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso (osimertinib) in untreated patients with epidermal growth factor receptor (EGFR)
AstraZeneca’s Imfinzi cancer immunotherapy has hit the mark in a phase 3 trial in extensive-stage small cell lung cancer, setting up a potential rivalry with Roche’s PD-L1 class drug Tecent
Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria co
